Translational predictions for brain therapeutics
Most CNS programs chase the wrong indication, patients or endpoints. Theremia predicts where your molecule is most likely to work.
We rank the diseases and phenotypes it could address, explain the biology behind each call, and hand you biomarkers to track it. You commit preclinical budget on evidence, not a hunch.
What changes with Theremia
Shorter programs, lower spend, better odds in Clinical phases.
preclinical R&D reduction
R&D cost savings
Phase 2 success rate
What you'll get
The concrete insights Theremia will provide on your drug
Example on your drug X, a brain-penetrant modulator of a neuroinflammatory pathway. Deep dive into any deliverable to discover the insights generated by Theremia's solution. Synthetic data but the format is real.
What is the most promising indication target for your drug?
Our solution ranks Parkinson's disease as the #4 indication for your drug X out of ~26,000, ahead of two of your initial targets.
- #4 · Parkinson's disease · Disease pathology directly triggers the drug's inflammatory pathwayStrong · New
- #12 · Alzheimer's disease · Different trigger, shared downstream inflammatory effectorModerate
- #27 · Amyotrophic lateral sclerosis (your initial target) · Partial overlap on the same microglial pathwayModerate
- #44 · Progressive MS · Smouldering microglial inflammation, distinct from relapsing MSModerate
Illustrative samples with synthetic data, shaped like real Theremia deliverables. Not actual predictions.
Request a pilot analysis
Discover on which positioning your asset can become tomorrow's blockbuster
Tell us about your molecule and what a useful result would look like. We reply within two business days, and everything is treated as confidential.